BEAM
Beam Therapeutics Inc.
$29.03
-1.29%
$3.0B
No data for this timeframe.
Vol
Market Cap$3.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders50 funds
Inst. Value$1.8B
Inst. Activity12 buys / 7 sells
Insider Activity0B / 9S
Insider Net $-$3.7M
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001745999·Prev Close $29.41
Recent Activity
Jun 12, 2026
short_volume
Short Volume: BEAM — 80.4% short (0.5M / 0.6M)
Short: 459,655 | Exempt: 12,922 | TRF Vol: 571,829 | Short Ratio: 80.4% | Off-exchange volume (dark
Jun 3, 2026
Insider
Shaw Christi was granted 19,676 shares
Director
Jun 3, 2026
Insider
Walsh Kathleen E was granted 19,676 shares
Director
Jun 3, 2026
Insider
Fishman Mark was granted 19,676 shares
Director
May 12, 2026
Press
Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog
Impact 7/10
Apr 17, 2026
SEC
Beam Therapeutics Inc. (BEAM) has filed its definitive proxy statement (DEFA14A) for the 2026 annual meeting. The filing
DEFA14A — Impact 3/10
Mar 5, 2026
SEC
Beam Therapeutics Inc. (BEAM) and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Pale
8-K — Impact 4/10
Inst.
BANK OF AMERICA CORP — ADD
538,290 shares ($12.8M)
Price Targets
$51.07
+75.9% upside
Strong Buy
Current $29.03
Low $26.00
Median $47.00
High $80.00
15 analysts
$26.00
$80.00
Analyst Ratings
11Strong Buy
11Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Outperform → Outperform |
| Mar 26, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Feb 25, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| Feb 25, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Feb 20, 2026 | Canaccord Genuity | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.13 ▼ -8.5% | $-1.24 — $-0.95 | -13% YoY | 13 |
| Next Q | $-1.18 ▼ -9.0% | $-1.28 — $-0.96 | -7% YoY | 13 |
| Current FY | $-4.47 ▼ -3.6% | $-4.76 — $-3.80 | -452% YoY | 15 |
| Next FY | $-4.74 ▼ -8.1% | $-5.90 — $-3.86 | -6% YoY | 13 |
Latest Reports
BULLISH
Press
7/10
Beam Therapeutics announced it will present updated biomarker data from the BEACON Phase 1/2 trial of ristoglogene autog
May 12, 2026
NEUTRAL
DEFA14A
3/10
Beam Therapeutics Inc. (BEAM) has filed its definitive proxy statement (DEFA14A) for the 2026 annual meeting. The filing
Apr 17, 2026
NEUTRAL
8-K
4/10
Beam Therapeutics Inc. (BEAM) and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Pale
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $296.7M | — |
| ARK Investment Management LLC | $289.1M | — |
| FARALLON CAPITAL MANAGEMENT LLC | $241.5M | EXIT |
| BlackRock, Inc. | $202.3M | — |
| STATE STREET CORP | $135.8M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Shaw Christi | A | $0.00 |
| Jun 3, 2026 | Walsh Kathleen | A | $0.00 |
| Jun 3, 2026 | Fishman Mark | A | $0.00 |
| Jun 3, 2026 | MARAGANORE JOHN | A | $0.00 |
| Apr 1, 2026 | Evans John | SELL | $739.3K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $1.8B total value (74,703,748 shares) as of 2026-Q1. Top holders: FMR, ARK, FARALLON. Net buying activity: 12 institutions added/increased vs 7 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 12,452,199 | $296.7M | 16.7% | — |
| 2 | ARK Investment Management LLC | 12,133,433 | $289.1M | 16.2% | — |
| 3 | FARALLON CAPITAL MANAGEMENT LLC | 10,134,696 | $241.5M | 13.6% | EXIT -100.0% |
| 4 | BlackRock, Inc. | 8,487,569 | $202.3M | 11.4% | — |
| 5 | STATE STREET CORP | 5,699,265 | $135.8M | 7.6% | ADD +30.4% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,570,797 | $108.9M | 6.1% | — |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 4,377,374 | $104.3M | 5.9% | — |
| 8 | Sumitomo Mitsui Trust Group, Inc. | 3,825,585 | $91.2M | 5.1% | — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 2,154,575 | $51.3M | 2.9% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 1,210,853 | $28.9M | 1.6% | DOUBLED +195.6% |
| 11 | GOLDMAN SACHS GROUP INC | 1,005,743 | $24.0M | 1.3% | — |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 808,436 | $19.3M | 1.1% | — |
| 13 | VANGUARD FIDUCIARY TRUST CO | 684,870 | $16.3M | 0.9% | — |
| 14 | MORGAN STANLEY | 648,264 | $15.4M | 0.9% | TRIM -50.7% |
| 15 | RTW INVESTMENTS, LP | 570,394 | $13.6M | 0.8% | NEW |
| 16 | BANK OF AMERICA CORP /DE/ | 538,290 | $12.8M | 0.7% | ADD +26.0% |
| 17 | CITADEL ADVISORS LLC | 528,970 | $12.6M | 0.7% | — |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 513,578 | $12.2M | 0.7% | DOUBLED +228.2% |
| 19 | BAILLIE GIFFORD & CO | 385,891 | $9.2M | 0.5% | ADD +39.8% |
| 20 | Pictet Asset Management Holding SA | 297,504 | $6.5M | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 427,328 | 538,290 | +26.0% | $12.8M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 156,500 | 513,578 | +228.2% | $12.2M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 22,128 | 144,722 | +554.0% | $3.4M | 2026-Q1 |
| MARSHALL WACE, LLP | NEAR_EXIT | 945,829 | 139,241 | -85.3% | $3.3M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | DOUBLED | 64,056 | 135,166 | +111.0% | $3.2M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | DOUBLED | 39,501 | 93,253 | +136.1% | $2.2M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 16,207 | 47,310 | +191.9% | $1.1M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 31,532 | 42,194 | +33.8% | $1.0M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | TRIM | 56,091 | 41,493 | -26.0% | $988.8K | 2026-Q1 |
| Concurrent Investment Advisors, LLC | NEAR_EXIT | 76,825 | 11,641 | -84.8% | $277.4K | 2026-Q1 |
| CWM, LLC | ADD | 2,466 | 4,364 | +77.0% | $104.0K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 8,952 | 3,216 | -64.1% | $76.6K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 277 | 3,145 | +1035.4% | $74.9K | 2026-Q1 |
| Rockefeller Capital Management L.P. | ADD | 1,299 | 2,532 | +94.9% | $60.3K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 1,152 | 1,524 | +32.3% | $36.3K | 2026-Q1 |
| HRT FINANCIAL LP | ADD | 151,183 | 219,426 | +45.1% | $5.2K | 2026-Q1 |
| FEDERATED HERMES, INC. | TRIM | 95 | 24 | -74.7% | $572.00 | 2026-Q1 |
| Woodline Partners LP | EXIT | 993,066 | 0 | -100.0% | $0.00 | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | EXIT | 492,430 | 0 | -100.0% | $0.00 | 2026-Q1 |
| STATE STREET CORP | ADD | 4,008,658 | 5,228,529 | +30.4% | $144.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 379,044 | 1,120,389 | +195.6% | $31.1M | 2025-Q4 |
| Woodline Partners LP | ADD | 546,559 | 993,066 | +81.7% | $27.5M | 2025-Q4 |
| MARSHALL WACE, LLP | NEW | — | 945,829 | — | $26.2M | 2025-Q4 |
| RTW INVESTMENTS, LP | NEW | — | 570,394 | — | $15.8M | 2025-Q4 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 1,260,011 | 492,430 | -60.9% | $13.7M | 2025-Q4 |
10 unique insiders with 30 transactions. Net insider value: -$3.7M ($0.00 bought, $3.7M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Shaw Christi | Director | AWARD | 19,676 | — | — |
| Jun 3, 2026 | Walsh Kathleen E | Director | AWARD | 19,676 | — | — |
| Jun 3, 2026 | Fishman Mark | Director | AWARD | 19,676 | — | — |
| Jun 3, 2026 | MARAGANORE JOHN | Director | AWARD | 19,676 | — | — |
| Apr 1, 2026 | Evans John M. | CEO | SELL | 30,078 | $24.58 | $739.3K |
| Apr 1, 2026 | Simon Amy | Chief Medical Officer | SELL | 6,700 | $24.58 | $164.7K |
| Apr 1, 2026 | Bellon Christine | Chief Legal Officer | SELL | 5,956 | $24.58 | $146.4K |
| Apr 1, 2026 | Cavanagh Bethany J | SVP, Finance and Treasurer | SELL | 3,242 | $24.58 | $79.7K |
| Apr 1, 2026 | Ciaramella Giuseppe | President | SELL | 11,810 | $24.58 | $290.3K |
| Mar 31, 2026 | Simon Amy | Chief Medical Officer | AWARD | 31,750 | — | — |
| Mar 31, 2026 | Ciaramella Giuseppe | President | AWARD | 40,000 | — | — |
| Mar 31, 2026 | Emany Sravan Kumar | Chief Financial Officer | AWARD | 31,750 | — | — |
| Mar 31, 2026 | Bellon Christine | Chief Legal Officer | AWARD | 20,000 | — | — |
| Mar 31, 2026 | Evans John M. | CEO | EXERCISE | 25,000 | $0.6700 | $16.8K |
| Mar 31, 2026 | Evans John M. | CEO | SELL | 25,000 | $22.76 | $569.1K |
| Mar 31, 2026 | Evans John M. | CEO | AWARD | 90,000 | — | — |
| Mar 31, 2026 | Cavanagh Bethany J | SVP, Finance and Treasurer | AWARD | 20,000 | — | — |
| Mar 30, 2026 | Evans John M. | CEO | EXERCISE | 25,000 | $0.6700 | $16.8K |
| Mar 30, 2026 | Evans John M. | CEO | SELL | 25,000 | $22.37 | $559.2K |
| Feb 24, 2026 | Ciaramella Giuseppe | President | EXERCISE | 35,000 | $17.00 | $595.0K |
| Jan 31, 2026 | Simon Amy | Chief Medical Officer | AWARD | 88,500 | — | — |
| Jan 31, 2026 | Emany Sravan Kumar | Chief Financial Officer | AWARD | 63,500 | — | — |
| Jan 31, 2026 | Ciaramella Giuseppe | President | AWARD | 80,000 | — | — |
| Jan 31, 2026 | Evans John M. | CEO | AWARD | 180,000 | — | — |
| Jan 31, 2026 | Bellon Christine | Chief Legal Officer | AWARD | 40,000 | — | — |
| Jan 31, 2026 | Cavanagh Bethany J | SVP, Finance and Treasurer | AWARD | 40,000 | — | — |
| Jan 30, 2026 | Evans John M. | CEO | EXERCISE | 25,000 | $0.6700 | $16.8K |
| Jan 30, 2026 | Evans John M. | CEO | SELL | 22,094 | $28.27 | $624.7K |
| Jan 29, 2026 | Evans John M. | CEO | EXERCISE | 19,336 | $0.6700 | $13.0K |
| Jan 29, 2026 | Evans John M. | CEO | SELL | 16,333 | $29.19 | $476.8K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.5/10.
Current analyst consensus: Strong Buy (88% buy). Based on 25 analysts: 11 strong buy, 11 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$51.07 mean target
+75.9% upside
Strong Buy (1.29)
$26.00 Low
$80.00 High
| Metric | Value |
|---|---|
| Current Price | $29.03 |
| Target Low | $26.00 |
| Target Mean | $51.07 |
| Target Median | $47.00 |
| Target High | $80.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.13 | $-1.24 | $-0.95 | -13.4% | -8.5% | 2↑ 8↓ | $0.0B | 89.8% | 13 |
| Next Q 2026-09-30 |
$-1.18 | $-1.28 | $-0.96 | -7.4% | -9.0% | 2↑ 8↓ | $0.0B | 66.7% | 13 |
| Current FY 2026-12-31 |
$-4.47 | $-4.76 | $-3.80 | -451.7% | -3.6% | 7↑ 5↓ | $0.1B | -47.6% | 15 |
| Next FY 2027-12-31 |
$-4.74 | $-5.90 | $-3.86 | -6.2% | -8.1% | 5↑ 6↓ | $0.1B | 19.3% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.134 | |
| 7d ago | $-1.134 | |
| 30d ago | $-1.045 | -0.089 |
| 60d ago | $-1.045 | -0.089 |
| 90d ago | $-1.046 | -0.088 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Feb 25, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Feb 20, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Jan 21, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Jan 7, 2026 | UBS | INITIATE | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Apr 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Mar 1, 2026 | 11 | 11 | 3 | 0 | 0 | 88% | |
| Feb 1, 2026 | 11 | 10 | 3 | 0 | 0 | 88% | |
| Jan 1, 2026 | 10 | 10 | 3 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
What if the next AI is genetics?
▲ 1
💬 0
⚡ 0.5
What if the next AI is genetics?
▲ 1
💬 0
⚡ 0.5
Jun 12, 2026
short_volume
Short Volume: BEAM — 80.4% short (0.5M / 0.6M)
Short: 459,655 | Exempt: 12,922 | TRF Vol: 571,829 | Short Ratio: 80.4% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: BEAM — 69.4% short (0.5M / 0.7M)
Short: 500,071 | Exempt: 6,435 | TRF Vol: 720,283 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: BEAM — 65.3% short (0.4M / 0.5M)
Short: 351,977 | Exempt: 0 | TRF Vol: 539,115 | Short Ratio: 65.3% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: BEAM — 65.9% short (0.4M / 0.6M)
Short: 408,712 | Exempt: 311 | TRF Vol: 620,299 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: BEAM — 69.1% short (0.7M / 1.0M)
Short: 669,364 | Exempt: 20,756 | TRF Vol: 969,289 | Short Ratio: 69.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: BEAM — 75.7% short (1.3M / 1.7M)
Short: 1,250,826 | Exempt: 2,477 | TRF Vol: 1,651,970 | Short Ratio: 75.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: BEAM — 63.5% short (0.5M / 0.7M)
Short: 458,394 | Exempt: 191 | TRF Vol: 722,120 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: BEAM — 68.7% short (0.4M / 0.5M)
Short: 367,066 | Exempt: 50 | TRF Vol: 533,946 | Short Ratio: 68.7% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: BEAM — 65.0% short (0.4M / 0.6M)
Short: 402,706 | Exempt: 3,290 | TRF Vol: 619,994 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: BEAM — 64.4% short (0.4M / 0.6M)
Short: 406,456 | Exempt: 1,156 | TRF Vol: 631,221 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: BEAM — 75.9% short (0.7M / 0.9M)
Short: 683,508 | Exempt: 10 | TRF Vol: 900,813 | Short Ratio: 75.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: BEAM — 65.5% short (0.4M / 0.6M)
Short: 387,674 | Exempt: 0 | TRF Vol: 591,745 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
fda
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and
May 18, 2026
short_volume
Short Volume: BEAM — 64.0% short (0.5M / 0.7M)
Short: 471,379 | Exempt: 200 | TRF Vol: 736,462 | Short Ratio: 64.0% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: BEAM — 65.0% short (0.5M / 0.8M)
Short: 503,315 | Exempt: 730 | TRF Vol: 774,148 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)